Literature DB >> 7600077

Enthesopathy and atypical gouty arthritis following renal transplantation: a case control study.

M R Cohen1, E P Cohen.   

Abstract

AIMS: To define associations and causative factors in a musculotendinous pain syndrome occurring after kidney transplantation.
METHODS: A case-control study was performed. Cases were identified clinically; transplant controls were matched for age, sex, date and type of transplant, and dialysis controls were matched for age, sex, and race.
RESULTS: All cases had enthesitis and five of seven later developed gouty arthritis. None of the controls had findings. The plasma uric acid was significantly greater in cases compared to both control groups.
CONCLUSIONS: A painful musculotendinous syndrome may occur after kidney transplantation. The development of gouty arthritis in five of the seven kidney transplant patients suffering from this syndrome and significant hyperuricemia compared with controls suggested an unusual pattern of gout arthropathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600077

Source DB:  PubMed          Journal:  Rev Rhum Engl Ed        ISSN: 1169-8446


  4 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Enthesopathy and tendinopathy in gout: computed tomographic assessment.

Authors:  J C Gerster; M Landry; G Rappoport; G Rivier; B Duvoisin; P Schnyder
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

Review 3.  Gout and organ transplantation.

Authors:  Lisa K Stamp; Peter T Chapman
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

4.  Succinic anhydride-based chemical modification making laccase@Cu3(PO4)2 hybrid nanoflowers robust in removing bisphenol A in wastewater.

Authors:  Huafang Yang; Peipei He; Youcheng Yin; Zhili Mao; Jing Zhang; Changle Zhong; Tian Xie; Anming Wang
Journal:  Bioprocess Biosyst Eng       Date:  2021-05-13       Impact factor: 3.210

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.